News

Prior to Novartis, Dr Brennan worked at Fidelity Biosciences and prior to that worked in business development for several early-stage biotechnology companies. Jeffrey Hatfield, CEO of Vitae Pharmaceuticals,

Emergent BioSolutions said that the contract is a two-year base period of performance valued at $54.6m and three option years that, if exercised by BARDA, would increase the

Biomagnetics claimed that the expected acquisition is the first of several planned acquisitions targeted at a $1.00 share price for company’s common shares. The company plans for rapid

Watson’s Sevelamer carbonate for oral suspension product is the generic version of Renvela for oral suspension from Genzyme. Renvela is a phosphate binder indicated for the control of

Under the collaboration, both the entities will utilise IMD’s database of biologically active natural substances and Bioprofiling technology platform to discover functional ingredients for specific food applications, and

The new relationship includes a series of four functional confection mixes that will incorporate GanedenBC30. Ganeden Biotech claims that GanedenBC30 has an ability to survive harsh manufacturing processes,

Benlysta is being jointly developed under a co-development and commercialisation agreement entered into, in 2006, by HGS and GlaxoSmithKline (GSK). Belimumab is an investigational human monoclonal antibody drug

The current development is a part of a research agreement signed in 2005 between Ablynx and Novartis, and has been extended by mutual agreement last year. Novartis is

With acquisition, A5 Labs has established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector. Richard Azani, president and CEO